Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors

Adoptive therapy with engineered T cells shows promising results in treating patients with malignant disease, but is challenged by incomplete responses and tumor recurrences. Here, we aimed to direct the tumor microenvironment in favor of a successful immune response by local secretion of interleuki...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunert, A., Chmielewski, M., Wijers, R., Berrevoets, C., Abken, H., Debets, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739571/
https://www.ncbi.nlm.nih.gov/pubmed/29296541
http://dx.doi.org/10.1080/2162402X.2017.1378842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739571/
https://www.ncbi.nlm.nih.gov/pubmed/29296541
http://dx.doi.org/10.1080/2162402X.2017.1378842

Ejemplares similares